Literature DB >> 8545524

The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety.

D M Walsh1, S C Stratton, F J Harvey, I J Beresford, R M Hagan.   

Abstract

The non-peptide NK2 receptor antagonist, GR159897, was evaluated in two putative models of anxiety, the mouse light-dark box and the marmoset human intruder response test. Effects were compared to the structurally dissimilar NK2 antagonist, (+/-) SR48968 and the benzodiazepines, diazepam and chlordiazepoxide. GR159897 (0.0005-50 micrograms/kg SC) caused significant and dose-dependent increases in the amount of time mice spent in the more aversive light compartment of the light-dark box, with no effect on locomotor activity. (+/-)SR48968 (0.0005-0.5 microgram/kg SC) and diazepam (1-1.75 mg/kg SC), also increased time spent in the light compartment, without effect on locomotor activity. In the marmoset human intruder response test, GR159897 (0.2-50 micrograms/kg SC) significantly increased the amount of time marmosets spent at the front of the cage during confrontation with a human observer ("threat"). Similar effects were produced by (+/-)SR48968 (10-50 micrograms/kg SC) and chlordiazepoxide (0.3-3.0 mg/kg SC). These results provide further evidence, in both rodent and primate species, for the ability of NK2 antagonists to restore behaviours which have been suppressed by novel aversive environments. Such effects indicate that NK2 antagonists may have anxiolytic activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8545524     DOI: 10.1007/bf02245629

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

1.  Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat.

Authors:  P Overton; P J Elliott; R M Hagan; D Clark
Journal:  Eur J Pharmacol       Date:  1992-03-17       Impact factor: 4.432

2.  A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.

Authors:  X Emonds-Alt; P Vilain; P Goulaouic; V Proietto; D Van Broeck; C Advenier; E Naline; G Neliat; G Le Fur; J C Brelière
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

3.  Effects of captopril and SQ29,852 on anxiety-related behaviours in rodent and marmoset.

Authors:  B Costall; A M Domeney; P A Gerrard; Z P Horovitz; M E Kelly; R J Naylor; D M Tomkins
Journal:  Pharmacol Biochem Behav       Date:  1990-05       Impact factor: 3.533

4.  Zacopride: anxiolytic profile in rodent and primate models of anxiety.

Authors:  B Costall; A M Domeney; P A Gerrard; M E Kelly; R J Naylor
Journal:  J Pharm Pharmacol       Date:  1988-04       Impact factor: 3.765

5.  Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors.

Authors:  R Dorow; R Horowski; G Paschelke; M Amin
Journal:  Lancet       Date:  1983-07-09       Impact factor: 79.321

Review 6.  Tachykinin receptors and tachykinin receptor antagonists.

Authors:  C A Maggi; R Patacchini; P Rovero; A Giachetti
Journal:  J Auton Pharmacol       Date:  1993-02

7.  Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: new tools for investigating neurokinin function.

Authors:  R M Hagan; S J Ireland; C C Jordan; I J Beresford; M J Deal; P Ward
Journal:  Neuropeptides       Date:  1991-06       Impact factor: 3.286

8.  The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.

Authors:  J Bradwejn; D Koszycki; A Couëtoux du Tertre; H van Megen; J den Boer; H Westenberg
Journal:  Arch Gen Psychiatry       Date:  1994-06

9.  The NK2 receptor antagonist SR48968 inhibits thalamic responses evoked by thermal but not mechanical nociception.

Authors:  V Santucci; C Gueudet; X Edmonds-Alt; J C Brelière; P Soubrié; G Le Fur
Journal:  Eur J Pharmacol       Date:  1993-06-11       Impact factor: 4.432

10.  Exploration of mice in a black and white test box: validation as a model of anxiety.

Authors:  B Costall; B J Jones; M E Kelly; R J Naylor; D M Tomkins
Journal:  Pharmacol Biochem Behav       Date:  1989-03       Impact factor: 3.533

View more
  4 in total

1.  Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat.

Authors:  Liliane J Dableh; Kiran Yashpal; Joseph Rochford; James L Henry
Journal:  Eur J Pharmacol       Date:  2004-12-28       Impact factor: 4.432

2.  Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats.

Authors:  M Toulouse; A M Coelho; J Fioramonti; A Lecci; C Maggi; L Buéno
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 3.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Assessing anxiety in nonhuman primates.

Authors:  Kristine Coleman; Peter J Pierre
Journal:  ILAR J       Date:  2014
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.